Emtricitabine News and Research

RSS
Emtricitabine, also known as Emtriva or FTC, is a type of medicine called a nucleoside reverse transcriptase inhibitor (NRTI). NRTIs block reverse transcriptase, a protein that HIV needs to make more copies of itself. Emtricitabine in capsule form was approved by the FDA on July 2, 2003, for use with other antiretroviral agents in the treatment of HIV infection in adults. Emtricitabine oral solution was approved by the FDA on September 28, 2005, and is now approved for use with other anti-HIV drugs in the treatment of HIV-1 infection in patients older than 3 months of age. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
Maraviroc drug safe, well-tolerated when taken as PrEP to prevent HIV infection

Maraviroc drug safe, well-tolerated when taken as PrEP to prevent HIV infection

Genvoya approved as complete regimen for HIV treatment

Genvoya approved as complete regimen for HIV treatment

HIV prevention program undergoes “real world” evaluation

HIV prevention program undergoes “real world” evaluation

Young, single South African women adhere well to daily PrEP regimen to prevent HIV infection

Young, single South African women adhere well to daily PrEP regimen to prevent HIV infection

ViiV Healthcare initiates Phase III trial to evaluate dolutegravir and rilpivirine in HIV patients

ViiV Healthcare initiates Phase III trial to evaluate dolutegravir and rilpivirine in HIV patients

US health care providers reluctant to prescribe HIV prevention plan

US health care providers reluctant to prescribe HIV prevention plan

HIV Prevention Trials Network launches two phase 2 studies to evaluate new HIV drugs

HIV Prevention Trials Network launches two phase 2 studies to evaluate new HIV drugs

NIH-sponsored clinical trials examine safety, acceptability of HIV antiretroviral medicines

NIH-sponsored clinical trials examine safety, acceptability of HIV antiretroviral medicines

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

New NIH funding to help researchers develop drug delivery system to prevent HIV infection in women

New NIH funding to help researchers develop drug delivery system to prevent HIV infection in women

Three-drug regimen taken during pregnancy prevents mother-to-child HIV transmission

Three-drug regimen taken during pregnancy prevents mother-to-child HIV transmission

MSD announces Phase 2b results of doravirine therapy in untreated patients with HIV-1 infection

MSD announces Phase 2b results of doravirine therapy in untreated patients with HIV-1 infection

Dosing of antiretroviral medication to prevent HIV infection differs by sex

Dosing of antiretroviral medication to prevent HIV infection differs by sex

UCSF gets CDC grant to provide expert guidance to clinicians who prescribe anti-HIV medications

UCSF gets CDC grant to provide expert guidance to clinicians who prescribe anti-HIV medications

FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

New guidelines integrate biomedical advances and behavioral interventions for HIV people

New guidelines integrate biomedical advances and behavioral interventions for HIV people

Janssen, Viiv Healthcare to develop single tablet regimen for maintenance treatment of HIV

Janssen, Viiv Healthcare to develop single tablet regimen for maintenance treatment of HIV

Merck enrolls first patient in reformulated raltegravir Phase 3 trial for treatment of HIV-1 infection

Merck enrolls first patient in reformulated raltegravir Phase 3 trial for treatment of HIV-1 infection

Dolutegravir drug offers added benefit in HIV patients

Dolutegravir drug offers added benefit in HIV patients